click here<\/a>.<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":"
After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were\u00a0reduced by 23% in the 400mg BID group (p<0.01) In patients with higher baseline GGT, reduction in GGT levels was even greater with 29%\u00a0(p<0.01) Alkaline phosphatase (ALP) levels were reduced by 17% in the 400mg BID group\u00a0(p<0.001) To read the press release, please click…<\/p>\n","protected":false},"author":2,"featured_media":2675,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-2677","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\n
Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were\u00a0reduced by 23% in the 400mg BID group (p<0.01) In patients with higher baseline GGT, reduction in GGT levels was even greater with 29%\u00a0(p<0.01) Alkaline phosphatase (ALP) levels were reduced by 17% in the 400mg BID group\u00a0(p<0.001) To read the press release, please click...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-05T13:19:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-07T17:55:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\" \/>\n\t<meta property=\"og:image:width\" content=\"404\" \/>\n\t<meta property=\"og:image:height\" content=\"223\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease\",\"datePublished\":\"2018-11-05T13:19:07+00:00\",\"dateModified\":\"2020-10-07T17:55:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\"},\"wordCount\":73,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\",\"name\":\"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\",\"datePublished\":\"2018-11-05T13:19:07+00:00\",\"dateModified\":\"2020-10-07T17:55:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\",\"width\":404,\"height\":223},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/","og_locale":"en_US","og_type":"article","og_title":"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease - ANDERA PARTNERS","og_description":"After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were\u00a0reduced by 23% in the 400mg BID group (p<0.01) In patients with higher baseline GGT, reduction in GGT levels was even greater with 29%\u00a0(p<0.01) Alkaline phosphatase (ALP) levels were reduced by 17% in the 400mg BID group\u00a0(p<0.001) To read the press release, please click...","og_url":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2018-11-05T13:19:07+00:00","article_modified_time":"2020-10-07T17:55:07+00:00","og_image":[{"width":404,"height":223,"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","type":"image\/png"}],"author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease","datePublished":"2018-11-05T13:19:07+00:00","dateModified":"2020-10-07T17:55:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/"},"wordCount":73,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/","url":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/","name":"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","datePublished":"2018-11-05T13:19:07+00:00","dateModified":"2020-10-07T17:55:07+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","width":404,"height":223},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Promising results for the lead program of Genkyotex (BioDiscovery 3) in a fibrotic orphan disease"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/2677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=2677"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/2677\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media\/2675"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=2677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=2677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\")
<\/p>\n